Ubs Oconnor LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Ubs Oconnor LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$10.32 - $14.76 $931,194 - $1.33 Million	-90,232 Reduced 53.17%	79,460 $898,000
Q1 2025 May 15, 2025	SELL	$7.4 - $12.6 $22,207 - $37,812	-3,001 Reduced 1.74%	169,692 $1.96 Million
Q4 2024 Feb 14, 2025	BUY	$8.09 - $12.5 $300,470 - $464,262	37,141 Added 27.4%	172,693 $1.46 Million
Q3 2024 Nov 14, 2024	BUY	$9.46 - $15.39 $119,120 - $193,790	12,592 Added 10.24%	135,552 $1.57 Million
Q2 2024 Aug 14, 2024	BUY	$10.35 - $12.49 $423,936 - $511,590	40,960 Added 49.95%	122,960 $1.45 Million

Q1 2024 May 15, 2024	BUY	$11.07 - $16.04 $907,740 - $1.32 Million	82,000 New	82,000 $972,000

155

57.9M

1.21M

865K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $328M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.